Phase II Interim Analysis of FcRn Inhibitor Rozanolixizumab in Adult Patients With Primary Immune Thrombocytopenia
Source: 2017 American Society of Hematology Annual Meeting*

Conference Program

 

Slideset

Phase II Interim Analysis of FcRn Inhibitor Rozanolixizumab in Adult Patients With Primary Immune Thrombocytopenia

Most treatment-emergent adverse events were mild to moderate in adult ITP patients receiving 4 or 7 mg/kg of rozanolixizumab subcutaneously.
Format: Microsoft PowerPoint (.ppt)
File size: 227 KB
Date posted: 12/20/2017